Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Post-transplant cyclophosphamide mechanisms

Christopher Kanakry • 26 Oct 2019
COSTEM 2019
General Cyclophosphamide

Christopher Kanakry, MD, Center for Cancer Research, National Cancer Institute, Bethesda, MD, discusses optimizing timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation (HSCT). This interview was recorded at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Christopher Kanakry

1:51
Insights into the efficacy of different strategies to prevent acute & chronic GvHD
Christopher Kanakry • 28 Oct 2022
6:05
Is it possible to efficiently prevent GvHD with a modified PTCy dosing schedule?
Christopher Kanakry • 28 Oct 2022
1:35
Optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation
Christopher Kanakry • 25 Oct 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals